MedTrace Logo

Bicalutamide in Treating Patients With Metastatic Breast Cancer

NCT00468715 · Status: COMPLETED · Phase: PHASE2 · Type: INTERVENTIONAL · Enrollment: 28

Last updated 2022-08-03

Study results available
· View outcomes & findings →

Summary

RATIONALE: Androgens can cause the growth of breast cancer cells. Antihormone therapy, such as bicalutamide, may stop the adrenal glands from making androgens.

PURPOSE: This phase II trial is studying how well bicalutamide works in treating patients with metastatic breast cancer.

Conditions

Interventions

DRUG

bicalutamide

OTHER

diagnostic laboratory biomarker analysis

OTHER

immunohistochemistry staining method

Sponsors & Collaborators

Principal Investigators

  • Tiffany A. Traina, MD · Memorial Sloan Kettering Cancer Center

Study Design

Allocation
NA
Purpose
TREATMENT
Masking
NONE
Model
SINGLE_GROUP

Eligibility

Min Age
18 Years
Max Age
120 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2007-03-23
Primary Completion
2021-06-24
Completion
2021-06-24

Countries

  • United States

Study Locations

More Related Trials

Entities

Diseases
Companies

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT00468715 on ClinicalTrials.gov